Peptides DB
Research-centric peptide and protocol reference hub
Study 6 of 11Degarelix literatureSexual abuse : a journal of research and treatment · Observational2016

Predictive Ability of the Sexual Child Molestation Risk Assessment (SChiMRA+).

The SChiMRA+ can help identify individuals at risk for future sexual offenses against children, but its predictive ability may be limited by the nature of self-reported data.

Read at Sexual abuse : a journal of research and treatmentAdd to compare

Where it sits

this study against the rest of the degarelix corpus
0
Preclinical
9
Observational · this one
0
Open-label
2
Randomised
0
Reviews

Summary and findings

This study evaluated the predictive ability of the Sexual Child Molestation Risk Assessment (SChiMRA+) in identifying individuals at risk of acting on sexual urges toward children. The analysis included longitudinal data from two clinical trials involving 52 men with pedophilic disorder and 160 active users of child sexual abuse material. The findings suggest that SChiMRA+ can identify increased risk for future offending behavior.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
optimal cutoff of 4.5 on Part A for indicating heightened risk for sexually abusive actsn=2122016

Abstract

The authors’ words, as Sexual abuse : a journal of research and treatment supplied them

In the field of child sexual abuse prevention, there is a need for risk assessment tools that are time-sensitive and can predict an individual's risk of acting on sexual urges, whether this is watching child sexual abuse material (CSAM), interacting socially with a child for sexual purposes, or committing sexual abuse. We evaluated the predictive ability of the Sexual Child Molestation Risk Assessment (SChiMRA+), a self-report scale that assesses current motivation to act on sexual urges toward children (Part A) and captures past-week sexual behaviors toward children (Part B). Longitudinal data from two clinical trials aiming to reduce sexual behaviors toward children were analyzed; Priotab (testosterone-lowering medication; <i>n</i> = 52 men with pedophilic disorder; pseudonymized) and Prevent It (internet-delivered cognitive behavioral therapy; <i>n</i> = 160 active CSAM users; anonymous). A ROC analysis identified an optimal cutoff of 4.5 on Part A for indicating a clinically significant heightened risk for sexually abusive acts (same week: specificity 63.7%, sensitivity 83.7%, AUC = .802; next week: specificity 53.1%, sensitivity 83.0%, AUC = .727). These results indicate that SChiMRA+ part A can be used to identify increased risk for future offending behavior as well as probable ongoing CSAM use among self-identified help-seekers.

Background

This paper addresses the need for effective risk assessment tools in child sexual abuse prevention. Prior research has indicated a gap in reliable methods to predict an individual's risk of acting on sexual urges. The SChiMRA+ aims to fill this gap by assessing current motivations and past behaviors related to child sexual abuse.

Methods

The study analyzed longitudinal data from two clinical trials: Priotab with n=52 men with pedophilic disorder and Prevent It with n=160 active CSAM users. The SChiMRA+ consists of two parts, assessing motivation and past-week behaviors. The primary outcome measure was the predictive ability of Part A using ROC analysis.

Results

The ROC analysis identified an optimal cutoff of 4.5 on Part A for indicating a clinically significant heightened risk for sexually abusive acts. For the same week, the specificity was 63.7%, sensitivity was 83.7%, and AUC was .802. For the next week, specificity was 53.1%, sensitivity was 83.0%, and AUC was .727.

Interpretation

The findings suggest that SChiMRA+ Part A can effectively identify individuals at risk for future offending behavior, aligning with previous literature on risk assessment tools. However, the clinical significance of the identified cutoffs may be limited by the moderate specificity values. The reliance on self-reported data and small sample sizes may confound the results, limiting generalizability.

Key findings

  • optimal cutoff of 4.5 on Part A for indicating heightened risk for sexually abusive acts
  • same week: specificity 63.7%, sensitivity 83.7%, AUC = .802
  • next week: specificity 53.1%, sensitivity 83.0%, AUC = .727

Limitations

  • self-report measures may introduce bias
  • small sample size in both trials
  • results may not generalize beyond the studied populations
  • no long-term follow-up reported

Elsewhere in the Degarelix corpus

BApalutamide-Induced Pneumonitis Presenting as Severe Hypoxemic Respiratory Failure in Metastatic Prostate Cancer: A Case Report.Cureus · 2026 · n=1HumanBUltrasound localisation microscopy tracks testicular microvascular adaptations to endocrine function in male infertility.EBioMedicine · 2026 · n=63 · Vessel density p < 0.001 and diameter p < 0.01 were reduced in azoospermia irrespective of treatment.HumanBRelationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy. The BLADE studybiorxiv-preprint · 2023 · r=0.64, p=0.001 for FSH and appendicular lean mass index/fat body mass ratio.HumanAGonadotropin-releasing hormone antagonism reduces paedophilic interest through increased cerebellar activitybiorxiv-preprint · 2026 · r=-0.740, p<0.001 for correlation between cerebellar activation and reduction in paedophilic interest after degarelix.HumanAEffects of a Modified Injection Technique on Pain and Injection-Site Reactions to Degarelix Acetate in Patients with Advanced Prostate Cancerbiorxiv-preprint · 2026 · VAS pain score at 72 h: 0.9±0.5 in modified group vs 2.3±1.0 in standard group, p<0.001.HumanBMITF Gain-of-Function Mutation in Metastatic Prostate Cancer: A Rare Finding With Potential Therapeutic Significance.Cancer reports (Hoboken, N.J.) · 2023 · n=1 · Not reported in abstract.Human